Table 1. Patient clinicopathological characteristics.
| Characteristic | Total (n = 110) |
EGFRmt group (n = 51) |
EGFRwt group (n = 59) |
p value | |
|---|---|---|---|---|---|
| Age (years) | Median | 65 (38–76) | 64 (40–76) | 66 (38–75) | 0.754 |
| Sex | Male | 50 (45.5%) | 16 (31.4%) | 34 (57.6%) | 0.006 |
| Female | 60 (54.6%) | 35 (68.6%) | 25 (42.4%) | ||
| Follow-up (months) | Median | 56.8 (6.8–164.4) | 58.8 (7.7–162.3) | 50.8 (6.8–164.4) | 0.412 |
| Smoking history | No | 49 (44.6%) | 34 (66.7%) | 15 (25.4%) | <0.001 |
| Yes | 61 (55.5%) | 17 (33.3%) | 44 (74.6%) | ||
| Resection | Lobectomy | 95 (86.4%) | 47 (92.2%) | 48 (81.4%) | 0.176 |
| Bilobectomy | 1 (0.9%) | 1 (2.0%) | 0 (0%) | ||
| Segmentectomy | 1 (0.9%) | 0 (0%) | 1 (1.7%) | ||
| Lobectomy with chest wall resection | 4 (3.6%) | 0 (0%) | 4 (6.8%) | ||
| Sleeve lobectomy | 8 (7.3%) | 3 (5.9%) | 5 (8.5%) | ||
| Pneumonectomy | 1 (0.9%) | 0 (0%) | 1 (1.7%) | ||
| Cisplatin cycle | 1–2 | 25 (22.7%) | 9 (17.7%) | 16 (27.1%) | 0.263 |
| 3–4 | 85 (77.3%) | 42 (82.4%) | 43 (72.9%) | ||
| Histology | Adenocarcinoma | 100 (90.9%) | 48 (94.1%) | 52 (88.1%) | 0.334 |
| Others (adenosquamous cell carcionoma, pleomorphic carcinoma) | 10 (9.1%) | 3 (5.9%) | 7 (11.9%) | ||
| pStage | I | 2 (1.8%) | 1 (2.0%) | 1 (1.7%) | 0.872 |
| IIB | 52 (47.3%) | 22 (43.1%) | 30 (50.9%) | ||
| IIIA | 46 (41.8%) | 23 (45.1%) | 23 (39.0%) | ||
| IIIB | 10 (9.1%) | 5 (9.8%) | 5 (8.5%) | ||
| pT | 1 | 37 (33.6%) | 21 (41.2%) | 16 (27.1%) | 0.005 |
| 2 | 35 (31.8%) | 21 (41.2%) | 14 (23.7%) | ||
| 3 | 30 (27.3%) | 8 (15.7%) | 22 (37.3%) | ||
| 4 | 8 (7.3%) | 1 (2.0%) | 7 (11.9%) | ||
| pN | 0 | 27 (24.6%) | 4 (7.8%) | 23 (39.0%) | <0.001 |
| 1 | 38 (34.6%) | 20 (39.2%) | 18 (30.5%) | ||
| 2 | 45 (40.9%) | 27 (52.9%) | 18 (30.5%) | ||
| Pleural invasion | 0 | 64 (58.2%) | 30 (58.8%) | 34 (57.6%) | 0.041 |
| 1 | 28 (25.5%) | 16 (31.4%) | 12 (20.3%) | ||
| 2 | 7 (6.4%) | 4 (7.8%) | 3 (5.1%) | ||
| 3 | 11 (10.0%) | 1 (2.0%) | 10 (17.0%) | ||
| Lymphatic invasion | Absence | 80 (72.7%) | 37 (72.6%) | 43 (72.9%) | 0.969 |
| Presence | 30 (27.3%) | 14 (27.5%) | 16 (27.1%) | ||
| Vascular invasion | Absence | 54 (49.1%) | 24 (47.1%) | 30 (50.9%) | 0.692 |
| Presence | 56 (50.9%) | 27 (52.9%) | 29 (49.2%) | ||
| Pulmonary metastasis | Absence | 97 (88.2%) | 46 (90.2%) | 51 (86.4%) | 0.572 |
| Presence | 13 (11.8%) | 5 (9.8%) | 8 (13.6%) | ||
| Histological predominance | Lepidic | 4 (3.6%) | 2 (3.9%) | 2 (3.4%) | <0.001 |
| Acinar | 17 (15.5%) | 11 (21.6%) | 6 (10.2%) | ||
| Papillary | 40 (36.4%) | 26 (51.0%) | 14 (23.7%) | ||
| Solid | 28 (25.5%) | 6 (11.8%) | 22 (37.3%) | ||
| Micropapillary | 8 (7.3%) | 4 (7.8%) | 4 (6.8%) | ||
| Others | 13 (11.8%) | 2 (3.9%) | 11 (18.6%) | ||
| Micropapillary patterns | Absence | 40 (36.4%) | 9 (17.7%) | 31 (52.5%) | <0.001 |
| Presence | 70 (63.6%) | 42 (82.4%) | 28 (47.5%) | ||
| Solid patterns | Absence | 48 (43.6%) | 25 (49.0%) | 23 (39.0%) | 0.438 |
| Presence | 62 (56.4%) | 26 (51.0%) | 36 (61.0%) | ||
| EGFR mutation | Exon 18 | 2 (3.9%) | |||
| Exon 19 | 30 (58.8%) | ||||
| Exon 21 | 19 (37.3%) | ||||
EGFR: epidermal growth factor receptor; EGFRmt: EGFR mutation; EGFRwt: EGFR wild type